|

CD19/BCMA Targeted CAR T-cells Clinical Trials

2 actively recruiting trials

Also known as: CD19/BCMA Targeted CAR T-cells infusion, RD06-05

Pipeline

Early 1: 2

Top Sponsors

  • Zhejiang University1
  • Daishi Tian1

Indications

  • Cancer2
  • Autoimmune Encephalitis (AE)1
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1
  • Myasthenia Gravis (MG)1
  • Relapsing or Refractory Multiple Sclerosis (MS)1

Other2 trials

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Early 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.